UPDATE
03-Jul-2012 By Natalie Morrison
Cutting in-house R&D staff to outsource more activities cuts will drive the industry forward, according to a new report.
28-Jun-2012 By Nick Taylor
A shortage of staff to serve strategic deals will drive big CROs to scale and consolidate through M&A, an analyst predicts.
UPDATE
27-Jun-2012 By Natalie Morrison
“Collaborate to innovate,” is the message DIA has for clinical researchers at its 2012 Annual Meeting in Philadelphia, US.
25-Jun-2012 By Natalie Morrison
Catalent and Bend Research have joined forces to tackle time and cost restrictions for the complex oral controlled-release development and manufacturing process.
13-Jun-2012 By Natalie Morrison
SAFC has coupled its chiral screening and small-scale purification services to meet what it says is a boom in demand for more complete chemical analysis from drugmakers.
11-Jun-2012 By Nick Taylor
S&P thinks PRA will use the flexibility in its new credit facility to grow its business through acquisitions.
07-Jun-2012 By Natalie Morrison
inVentiv Health will expand its digital and social media commercial services following the takeover of Kazaam Interactive.
05-Jun-2012
Outsourcing-Pharma presents a roundup of M&A activity in the CMO space, including Piramal on the hunt for deals and Siegfried buying AMP.
29-May-2012 By Natalie Morrison
Kemwell is set to complete a new biologics manufacturing facility in Bangalore, India, following its long-term partnership with Boehringer Ingelheim.
EXCLUSIVE
28-May-2012 By Natalie MORRISON
More than a third of patient recruitment will be done in emerging markets in the future, predicts Chiltern CEO Glenn Kerkhof.
21-May-2012 By Nick Taylor
The CEO of PDI said the contract sales market has “shrunk” over the past few quarters as the flow of business awards has dried up.
09-May-2012 By Nick Taylor
Increased oversight by the FDA is causing some US-based CMOs to shut down, a speaker at Interphex said.
07-May-2012 By Nick Taylor
The CEO of Charles River said asset transfer strategic deals make little “rational sense” to clients or CROs.
25-Apr-2012 By Natalie Morrison
The European CMO industry could be blocked by over complex layers of regulation, says Frost & Sullivan analyst Aiswariya Chidambaram.
Regulatory changes: the experts give us their thoughts at DIA Euromeeting
05-Apr-2012 By Natalie Morrison
Regulatory reform was the name of the game at this year’s DIA Euromeeting in Denmark.
03-Apr-2012 By Nick Taylor
INC Research and inVentiv Health must “quickly and effectively” integrate acquisitions to compete with other CROs, S&P said.
29-Mar-2012 By Natalie Morrison
“Less bureaucracy and more research” was the Danish Minister of science and innovation’s message to regulators at this week's DIA Euromeeting.
29-Mar-2012 By Nick TAYLOR
Cetero says it could have new private equity owners in 90 days and an agreed path forward with the FDA in weeks.
19-Mar-2012 By Nick Taylor
A SEC filing has created speculation that Medidata is the target of a private equity takeover attempt by Vista Equity Partners.
15-Mar-2012 By Natalie Morrison
The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost & Sullivan’s Aiswariya Chidambaram.
13-Mar-2012 By Natalie Morrison
Patheon took a $20.9m (€15.9m) Q1 hit in operating costs thanks to the loss of a major manufacturing supply agreement.
14-Feb-2012 By Nick Taylor
SeraCare Life Sciences has accepted an $82m offer from a US private equity firm six months after it began searching for a buyer.
07-Feb-2012 By Nick Taylor
Covance is investing to win business from “distracted competitors” that have been part of mergers and buyouts, an analyst claims.
24-Jan-2012 By Natalie Morrison
Outsourcing is a gamble for the industry that needs a closer collaborative approach if pharma firms want a successful performance, according to new research.
24-Jan-2012 By Nick Taylor
Preclinical CROs begin reporting full year results this week, with talk of takeovers and toxicology high on agendas.
Polytherics buys Warwick Effect Polymers for biodrug modification tech
23-Jan-2012
UK-based Polytherics has acquired Warwick Effect Polymers (WEP) to expand biologic drug modification offering.
12-Jan-2012 By Nick Taylor
Charles River’s CEO has reiterated the importance of integrating its research models and preclinical units but refused to discuss takeover reports.
11-Jan-2012 By Nick Taylor
Major CRO consolidation will slow down in 2012 after the big wave of deals last year, the CEO of Icon said.
10-Jan-2012 By Nick Taylor
Charles River is reportedly considering selling the business, with private equity and rival companies believed to be possible buyers.
09-Jan-2012
Toray Industries has acquired a stake in a Japanese CMO and ingredient supplier as part of its push into life sciences.
05-Jan-2012 By Nick Taylor
UK-based biotech ValiRx has acquired a biomarkers business from Finnish preclinical CRO Pharmatest Services.
15-Dec-2011 By Nick Taylor
Charles River wants to buy drug discovery assets to meet interest in strategic outsourcing of non-regulated efficacy testing.
Schulman Associates buys Florida IRB
06-Dec-2011
Cincinnati, US-based Schulman Associates Institutional Review Board (IRB) has bought Florida counterpart Independent Investigational Review Board (IIR) to broaden its offering for Pharmas and CROs.
UBC looking to ‘buy or build’ to serve strategic partnerships
29-Nov-2011 By Nick Taylor
UBC expects strategic outsourcing of outcomes and personalised medicine research to accelerate as biopharm cut fixed costs.
Forming CRO spin-outs can help big pharma; research
24-Nov-2011 By Nick Taylor
Spinning-out assets to form a CRO can help large biopharm commercialise knowledge and focus on core activities, research found.
SeraCare posts Q4 loss after bioservice revenue halves
21-Nov-2011 By Nick Taylor
SeraCare slipped into the red in the fourth quarter as loss of government business halved bioservice revenues.
UCB inks deal with Parexel & PRA to boost cost-effectiveness
16-Nov-2011 By Nick Taylor
UCB has inked a strategic deal with Parexel and PRA that an analyst believes has “very favourable” terms for the biopharm.
14-Nov-2011 By Nick Taylor
Patheon is considering buying unique drug delivery technologies to expand its development service capabilities.
PDI operating profit falls as DCA buy drags on performance
10-Nov-2011 By Nick Taylor
Operating profit at PDI fell 90 per cent in the third quarter after the acquired digital communications unit again dragged on performance.
07-Nov-2011 By Nick Taylor
Catalent is considering acquisitions as it adds scale, drug delivery technologies and capacity in emerging markets.
Effective outsourcers will have competitive edge in 2020; KPMG
26-Oct-2011 By Nick Taylor
Effectively outsourcing a significant portion of work will give biopharm a competitive advantage in 2020, KPMG said.
Quintiles makes acquisitions in observational research and market access space
20-Oct-2011 By Gareth Macdonald
Quintiles has bought its way into the observational research space with the acquisition of Outcome Sciences and strengthened its market access standing with the purchase of VCG & Associates.
JSS & Venn partner to offer transatlantic clinical services
19-Oct-2011
JSS Medical Research has bought Canadian assets from Venn Life Sciences as part of a joint-venture spanning North America and Europe.
Encorium seeks partner or PE buyer after loss of biz
10-Oct-2011 By Nick Taylor
Encorium is seeking a CRO partner or private equity buyer after the strategic outsourcing trend hit its revenues and cash reserves.
Akorn to enter India in five facility takeover deal
06-Oct-2011 By Nick Taylor
Akorn is to expand its CMO business into India and add sterile injectables capabilities by acquiring five manufacturing plants.
AmerisourceBergen to buy reimbursement services firm TheraCom for $250m
05-Oct-2011 By Gareth Macdonald
AmerisourceBergen will buy patient access and reimbursement support services firm TheraCom, continuing its recent run of acquisitions.
PPD accepts $3.9bn offer
04-Oct-2011 By Nick Taylor
PPD has agreed to be acquired by two private equity firms for $3.9bn (€3.0bn) in cash.
CEO hire signals private equity unlikely to buy PPD; analyst
20-Sep-2011 By Nick Taylor
PPD has named a new CEO and is now unlikely to be taken over by private equity because the deal environment has worsened, an equity analyst said.
Patheon plans facility exits & capability cuts to improve biz
13-Sep-2011 By Nick Taylor
Patheon is exiting semi-solids, clinical packaging and cutting facilities in response to ‘poor historical performance’.
inVentiv plans Asian expansion
31-Aug-2011 By Nick Taylor
inVentiv Health is looking to expand operations in Japan, China and India after completing takeovers of i3 and PharmaNet.
